News
November 18, 2024
PanFlu Wins BioTech Breakthrough Award For 2024 “Monoclonal Antibody Solution Of The Year”
PanFlu is the recipient of the “Monoclonal Antibody Solution of the Year” award in the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough.
October 11, 2024
Interview: CEO Koenraad Wiedhaup with Biotech TV’s Brad Loncar
CEO Koenraad Wiedhaup recently had the opportunity to share the mission of Leyden Labs with Brad Loncar of Biotech TV during a stop in Leiden on the team’s 2024 European Biotech Tour.
September 12, 2024
Leyden Labs Appoints Jintanat Ananworanich, M.D., Ph.D., as Chief Medical Officer
Dr. Ananworanich most recently led influenza vaccine development at Moderna and brings more than 20 years of clinical and industry experience in infectious disease.
February 16, 2024
New publication shows CR9114 protects against avian flu in mice
The ongoing spread of avian flu among animals has increased the urgency of developing products that could prevent infection in the event of an H5N1 pandemic.
January 8, 2024
Leyden Labs Selected to Present at 2024 J.P. Morgan Conference
Leyden Labs CEO Koenraad Wiedhaup will deliver a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024 in San Francisco, CA.
May 13, 2023
Leyden Labs Presenting at Bio€quity Europe 2023
We’re looking forward to presenting at BioCentury Inc.’s Bio€quity Europe 2023 in Dublin, Ireland. Our Co-Founder & CEO, Koenraad Wiedhaup, and CFO, Marieke van der Lans, will be sharing business updates, including the start of our Phase 1 clinical trial for our first PanFlu candidate.
April 19, 2023
Leyden Labs’ Intranasal PanFlu Antibody Enters the Clinic
Leyden Laboratories B.V., (the “Company” or “Leyden Labs”) announced today the dosing of the first Phase 1 healthy volunteer cohort with a nasal spray containing PanFlu candidate CR9114.
Februay 04, 2023
Modeling Covid vaccination strategies for endemic SARS-CoV-2
A new article from Leyden Labs has been published in the European Journal of Epidemiology.
January 06, 2023
Leyden Labs Presenting at 2023 J.P. Morgan Conference
We’re pleased to share that Leyden Labs CEO Koenraad Wiedhaup will present at the 41st Annual J.P. Morgan Healthcare Conference.
December 19, 2022
Leyden Labs among INSIDER’s list of 33 healthcare and biotech startups investors expect to take off in 2023
We are honored to be included in Insider’s list of inspiring healthcare and biotech companies in 2023.
November 02, 2022
New publication highlights the secret to CR9114’s pan-influenza protection
Recently, our article entitled “The influenza hemagglutinin stem antibody CR9114: Evidence for a narrow evolutionary path towards universal protection,” appeared in a special issue of Frontiers in Virology on the role of genetic and structural insights of neutralizing antibodies to guide viral vaccine design.
October 30, 2022
Population modeling reveals impact of antibody nasal sprays on new viruses like SARS-CoV-2
A new research article by Leyden Labs and partners at Imperial College has been published in Infectious Diseases & Therapy.
January 25, 2022
Leyden Labs Raises $200M in 2021 for a New Approach to Combat Viruses
Leyden Labs announces a $140M Series B financing led by Casdin Capital and GV (formerly Google Ventures) with participation from leading global life science investors. The proceeds accelerate development of products against a broad range of respiratory viruses through mucosal protection.
January 18, 2022
Leyden Labs Licenses Pan-Influenza Antibody from Janssen
Janssen’s CR9114 is a human monoclonal antibody that protects against influenza A & B. This exclusive license supports Leyden Labs’ mission to optimize mucosal protection against entire viral families to prevent future pandemics.
November 12, 2021
Leyden Labs now member of HollandBIO
HollandBIO represents and connects life science companies in the Netherlands and stimulates rapid accessibility of innovation. Over 200 companies are linked through this organization to work towards a better future. Recently, Leyden Labs has also become a member.
September 28, 2021
Leyden Labs among the Top 15 Biotech Companies in Amsterdam
Earlier this month Labiotech.eu published a Top 15 of Biotech Companies in Amsterdam. They have specifically put together a list of companies seeking to change the world. We are very proud to share this list with some of the biggest names in the Biotech Industry and several companies that have left the start-up phase years ago.
September 23, 2021
InvestInHolland pictures Leyden Labs in Dutch biotech ecosystem
InvestInHolland points out the vital role of the Netherlands in today’s global health system by going through the past, present and future of the Dutch pharmaceutical industry. They name Leyden Labs as an example of the future of pharmaceutical development and specifically highlight our mission to protect against many viruses at once.
August 3, 2021
Koenraad Wiedhaup (CEO) talks about Leyden Labs on the Business of Biotech podcast
Matthew Pillar interviews our CEO, Koenraad Wiedhaup, looking back at when Leyden Labs was founded, Koenraad's unique background and looking ahead to how our products can be complementary to vaccines.
July 26, 2021
Learn more about our intranasal approach on the Empowered Patient Podcast
In the Empowered Patient Podcast Karen Jacoda highlights latest innovations in healthcare, pharma and biotech and changing dynamics between patients and physicians in her podcast. For this episode, Karen interviewed our CEO Koenraad, who spoke about Leyden Labs' proactive approach toward viral threats.
July 21, 2021
Nanopharm and Leyden Labs Announce Agreement to Develop Intranasal Spray Product Candidates for Prophylactic Use Against Known and New Respiratory Viruses
To read the full press release, click below.
May 19, 2021
Our approach to protect against known and future viruses explained in Scrip
Leyden Labs was covered as Emerging Company Profile by Scrip. Sten Stovall discusses in his article how our novel intranasal medicine can potentially target viral families to prevent the next pandemic.
May 11, 2021
MedNous addressing multiple uses for Leyden Labs' nasal sprays
Last month, our CEO Koenraad Wiedhaup spoke with co-founder and editor of MedNous, Victoria English, about Leyden Labs. They discussed the development of our platform and portfolio of prophylactic nasal sprays and their potential role to prevent future pandemics.
May 6, 2021
Labiotech discussing our proactive approach
Victor Kotsev has evaluated a broad range of initiatives following the COVID-19 pandemic. He also highlights Leyden Labs' proactive approach toward viral diseases amongst a range of vaccine and treatment options.
April 28, 2021
Leyden Labs featured in BioSpace looking beyond COVID-19 pandemic
Heather McKenzie recently wrote an article about pandemic preparedness. She explores future threats and a collection of measures to protect against future outbreaks. You can read the full article on the BioSpace website.
April 13, 2021
Koenraad Wiedhaup and David Schenkein talk about Leyden Labs' approach to pandemic preparedness
Learn more about our story in the conversation between Koenraad Wiedhaup (CEO) and David Schenkein (General Partner at GV and board member at Leyden Labs). They discuss the mission and approach, investment round, fantastic team and plans for the future.
March 31, 2021
John Martin - In Memoriam
The passing of John Martin, who served as a member of our Supervisory Board came unexpectedly and has left us with great sadness. Our thoughts are with his family and his friends.
March 29, 2021
BioWorld published an article about our Series A
Cormac Sheridan wrote an article about our investment round with GV (formerly Google Ventures), F-Prime, Casdin Capital and Brook Byers. To learn more about our Series A and our story, visit the BioWorld website.
March 26, 2021
Leyden Labs' story covered in Endpoints News
Leading up to the public launch, our CEO Koenraad Wiedhaup spoke with Amber Tong of Endpoints News about Leyden Labs. An interesting read to learn more about our mission to free humanity from the burden of respiratory viruses.
March 25, 2021
Leyden Labs to Unlock a New Generation of Preventative Medicines against Known and Future Viruses by Securing a €40 Million Series A from GV (formerly Google Ventures), F-Prime and Casdin Capital
Funding to advance platform and portfolio of intranasal products that protect against a broad range of respiratory viruses, including influenza and coronaviruses, to let people live their lives freely
OUR NEW APPROACH | OUR TEAM | JOIN OUR MISSION | NEWS | CAREERS
Leyden Laboratories B.V.
Leiden Laboratory
Emmy Noetherweg 2
2333 BK Leiden
The Netherlands
© Leyden Labs, 2023 | Privacy Statement | Design by Ape to Zebra
